Anthera has switched gears as they recently disclosed that development program testing blisibimod in lupus is on hold as the company searches for a partner that will fund further development. This is a disappointment as ANTH had previously planned to start Phase III development for lupus this year. ANTH now says that that they are[…]
January 18, 2013 Below is a pdf for Issue 746 of the Medical Technology Stock Letter. [gview file=”http://50.87.166.114/wp-content/uploads/2013/03/MTSL-746-January-18-2013-3.pdf” save=”1″]
OUTLOOK 2013, RAISING BUY LIMIT AND TARGET PRICE As recently as the summer of 2012, Celgene had a stable but slowing core business led by Revlimid but no apparent pipeline. Questions arose about the companyâs long-term growth. In a remarkable turn of events, the company and stock have been revived by not one but three[…]
Our #1 pick for 2013 We met with Coronado Biosciences’ new CEO Harlan Weisman during JP Morgan. We have known Dr. Weisman since our days as a Centocor analyst in the 1990s where he was Chief Medical Officer and subsequently became Senior management at Johnson & Johnson (JNJ) after its acquisition of CNTO. With his[…]
On a positive note, Pacira pre-released some of their key Q4 financials. The company expects Q4:12 and FY12 revenues to come in above Wall Street consensus estimates, driven by higher net sales of Exparel. Q4 sales of the drug are targeted at $7.8 million, and total revenues are estimated at $10.5 million, compared to $4.2[…]
Incyte’s stock has had a nice move to start the year. The company presented at JP Morgan and did a good job of detailing how they will grow Jakafi sales. Importantly, some on Wall Street also believe that INCY has learned a lot from the launch over the last year and are positioned to grow[…]
With T-DM1 FDA approval nearing the goal line â the PDUFA date is February 26 â ImmunoGen will join the ranks of commercially successful biotech companies, a major achievement. While it is widely known that the royalty rate IMGN will receive from partner Roche (~3%) is unlikely to lead the company to major profitability, regulatory[…]
CONTINUED PROGRESS AND PIPELINE VISIBILITY. Nektar management continues to make progress across its lateâstage development pipeline, relieving some investor concern for the naloxegol (NKTR-118) program â NKTRâs lead compound â under development for the treatment of opioid-induced constipation (OIC). With renewed optimism on the â118 program and upcoming related catalysts, increasing appreciation of the breadth[…]
Isis’Â stock has been strong, pre- and post-JP Morgan. Wall Street is beginning to warm up to the story, as we believe; the deep pipeline from late-stage to early-stage compounds is attracting more investors. Â The recent partnerships with Biogen and AstraZeneca for certain early-stage drug development candidates have convinced some that antisense has real potential. The[…]
Sangamo’s stock has risen sharply (~35%) since their presentation last week at the JP Morgan conference. The company broadly explained what their novel technology – In Vivo Protein Replacement – has the ability to accomplish. It has the ability to mechanistically, physically, and permanently change a single disease related gene (“monogenic”) and, therefore, has substantial[…]
OUTLOOK 2013 â RAISING BUY LIMIT AND TARGET PRICE Over the past decade, Alkermes has evolved into a fully integrated company as they receive revenue from five ALKS-developed approved drugs and have established a real R&D pipeline. ALKS has emerged as a leader in the development of injectable antipsychotics that can be administered as infrequently[…]
OUTLOOK 2013 – THE OPEN-ENDED POTENTIAL OF ZFPS SGMO’s stock has exploded since their presentation last week at the JP Morgan conference. The company began the presentation by broadly explaining what their technology can accomplish. The ability to actually mechanistically, physically, and permanently change a single disease related gene (monogenic) has huge potential. SGMO’s technology[…]
